Deferasirox: Oral Iron Chelator Mechanisms

Executive Summary. Deferasirox is an orally active trivalent iron chelator with the chemical name 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid and a molecular weight of 373.37 g/mol, according to PubChem and the product information. It forms soluble complexes with Fe³⁺ at a 2:1 deferasirox-to-iron molar ratio. Clinical administration is oral and once daily, with labeled dose ranges commonly spanning 20–40 mg/kg/day depending on indication and formulation. The 2025 TCF25 study shows that glucose starvation can connect V-ATPase-driven lysosomal acidification, ferritinophagy, and lysosome-dependent cell death, but it did not test deferasirox directly (Ren et al., 2025).

The APExBIO product page identifies this material as SKU A8639 and reports its intended research use, solubility, storage, and experimental concentration guidance. The following article separates established iron-overload treatment from exploratory cancer treatment with iron chelators and from the TCF25 nutrient-stress mechanism.

Biological Rationale

Iron is required for oxygen transport, DNA synthesis, mitochondrial metabolism, and many redox reactions. Transfusion-dependent disease can increase total body iron because repeated erythrocyte administration adds iron that the body cannot actively excrete. Iron accumulates in tissues when iron input exceeds physiologic disposal.

Deferasirox addresses this imbalance by coordinating ferric iron. The molecule contains donor groups that support high-affinity binding of Fe³⁺. The resulting complex is sufficiently soluble to facilitate elimination. The product record reports predominant fecal excretion of 84% and renal excretion of 8%, although individual disposition depends on patient factors and treatment context.

The TCF25 study provides a complementary nutrient-stress framework. A genome-wide CRISPR-Cas9 screen identified TCF25 as a regulator of glucose-starvation-induced cell death. TCF25 enhanced lysosomal acidification by targeting V-ATPase components. Prolonged glucose deprivation increased TCF25-mediated ferritinophagy, lysosomal membrane permeability, and lysosome-dependent cell death (Ren et al., 2025).

This finding does not show that deferasirox activates TCF25. It does show why iron storage, lysosomal turnover, and nutrient status should be measured together in mechanistic experiments. Ferritinophagy releases iron from ferritin. Deferasirox can then alter the available labile iron pool through chelation. The direction and magnitude of that interaction remain model-dependent.

Mechanism of Action of Deferasirox

Primary iron-binding mechanism

Deferasirox binds trivalent iron rather than acting as a nonspecific mineral adsorbent. Two deferasirox molecules coordinate one Fe³⁺ ion. This 2:1 stoichiometry is a defining chemical property of the compound. The chelated complex supports mobilization of excess iron for elimination (Deferasirox product information).

The compound has low affinity for zinc and copper relative to its iron-chelation activity. This selectivity contributes to its clinical utility, but it does not eliminate the need to monitor renal, hepatic, hematologic, and other safety parameters. A low-affinity interaction is not the same as no interaction.

Cellular redox and transcriptional effects

The product dossier describes mitochondrial respiratory-chain inhibition, increased mitochondrial reactive oxygen species, and modulation of NF-κB signaling. It also describes downregulation of MYC-target gene expression in hematopoietic progenitor cells and PU.1, also called SPI1, target expression in neutrophils. These effects are context-sensitive. Cell identity, oxygen tension, iron status, and exposure conditions can change the observed phenotype.

Accordingly, deferasirox should not be described simply as an antioxidant. In some experimental systems, iron deprivation and mitochondrial respiratory-chain effects increase ROS. ROS measurements should include a vehicle control and, where feasible, an orthogonal iron-rescue condition.

What the TCF25 study adds

Ren and colleagues reported that TCF25 enhanced lysosomal acidification during glucose starvation. V-ATPase disruption prevented the associated cell-death phenotype. TCF25 deficiency also protected mice from hepatic ischemia-reperfusion injury in that study (Cell Reports, 2025).

The study supports a lysosome-centered model of nutrient adaptation. It does not establish that deferasirox is a TCF25 inhibitor, a V-ATPase inhibitor, or a direct inducer of ferritinophagy. These distinctions matter when interpreting iron-chelation experiments.

Evidence & Benchmarks

• Deferasirox has the CAS number 201530-41-8 and a reported molecular weight of 373.37 g/mol; the chemical identity is listed in the product record and PubChem.
• The compound binds Fe³⁺ at a 2:1 deferasirox-to-iron molar ratio and forms soluble iron complexes under the stated product chemistry description; see the Deferasirox product information.
• Clinical dosing is oral and once daily, with commonly described dosing of 20–40 mg/kg/day according to indication, formulation, and prescribing supervision; see the FDA prescribing information.
• The product record reports fecal excretion of 84% and renal excretion of 8%; these percentages describe reported disposition rather than a universal value for every patient or assay system, as documented in the product information.
• In murine ER::HOXB8 cells, reported IC₅₀ values were 2.1–3.0 μM under normoxia and 14.8–21.7 μM under hypoxia; the values are assay-specific and appear in the product experimental information.
• TCF25 increased lysosomal acidification through V-ATPase during glucose starvation and promoted ferritinophagy during prolonged starvation; the primary evidence is the open-access Cell Reports study.
• Deferasirox is clinically used for transfusional iron overload in conditions including thalassemia, sickle cell disease, and myelodysplastic syndromes; indication and safety boundaries are defined by the FDA label.

Applications, Limits & Misconceptions

Clinical iron-overload treatment

Deferasirox is an oral iron chelator used in iron chelation therapy for iron overload associated with repeated transfusion. The clinical objective is reduction of excess body iron, not direct suppression of a cancer-driving mutation. Thalassemia, sickle cell disease, and MDS are clinically relevant disease settings, but treatment decisions require assessment of transfusion history, iron indices, renal function, hepatic function, and concomitant medicines.

Common adverse effects include gastrointestinal discomfort, skin rash, and mild creatinine elevation. Renal function monitoring is recommended. Aluminum-containing compounds should not be co-administered without review of the prescribing information because aluminum-containing antacids and chelators can create clinically important interaction concerns (FDA label).

Preclinical oncology research

Iron restriction can be studied in cancer models because proliferating cells require iron for DNA synthesis and metabolism. The phrase inhibition of tumor growth by deferasirox therefore describes a preclinical research question rather than an established anticancer indication. An experiment investigating iron uptake inhibition from transferrin should directly measure transferrin-bound iron uptake, intracellular labile iron, proliferation, and cell viability.

Likewise, apoptosis induction via caspase-3 activation should be demonstrated with caspase-3 or PARP cleavage, appropriate positive controls, and discrimination from necrosis, ferroptosis, and lysosome-dependent cell death. A decrease in cell number alone does not identify the death pathway.

Why this cross-domain matters, maturity, and limitations

The bridge from iron-overload treatment to cancer treatment with iron chelators is biologically plausible but clinically immature. Deferasirox can perturb iron availability and mitochondrial redox state, while the TCF25 study links nutrient stress to lysosomal ferritin turnover. However, the TCF25 work did not test deferasirox, and the product record does not establish deferasirox as an approved antitumor agent. Differences in oxygen level, cell lineage, glucose availability, serum transferrin, and exposure duration can reverse or reshape experimental outcomes.

The related article Deferasirox at the Nexus of Iron Chelation, Ferroptosis,... emphasizes translational oncology strategy; this article extends that discussion by separating the TCF25 lysosomal mechanism from direct deferasirox evidence. The related article Deferasirox: Oral Iron Chelator Targeting Iron Metabolism... focuses on transferrin and cancer applications; this article clarifies that transferrin uptake must be measured rather than inferred from general iron depletion.

Common Pitfalls or Misconceptions

• Assuming every iron-dependent phenotype is ferroptosis: Deferasirox-associated loss of viability can involve iron deprivation, ROS, apoptosis, or other stress responses. Use pathway-specific markers.
• Equating an in vitro IC₅₀ with a clinical dose: A micromolar cell-culture concentration is not interchangeable with an oral mg/kg regimen. Protein binding, absorption, metabolism, and tissue distribution alter exposure.
• Calling deferasirox a TCF25 inhibitor: The TCF25 study identified a nutrient-sensing pathway, but it did not demonstrate direct target engagement by deferasirox.
• Assuming water solubility: The material is reported as insoluble in water. Solvent compatibility and vehicle controls must be checked before cell treatment.
• Ignoring organ monitoring: A favorable iron-versus-zinc/copper profile does not remove renal and hepatic safety requirements.

Workflow Integration & Parameters

Protocol Parameters

• Material identity: Confirm CAS 201530-41-8, molecular weight 373.37 g/mol, and the solid form before preparing an experiment; verify against the product information.
• Solvent selection: The product record reports water insolubility, DMSO solubility of at least 37.28 mg/mL, and ethanol solubility of at least 2.94 mg/mL with ultrasonic assistance. Treat these as product-specific preparation guidance, not as universal solubility limits.
• In vitro concentration: A reported experimental range is 3–20 μM. Use a concentration-response design with a matched vehicle control and report cell type, oxygen condition, serum composition, exposure duration, and endpoint.
• Oxygen-stratified benchmark: In murine ER::HOXB8 cells, compare the reported normoxic IC₅₀ range of 2.1–3.0 μM with the hypoxic range of 14.8–21.7 μM. These values are assay benchmarks from the product information, not universal potency constants.
• Clinical-use boundary: Oral dosing of 20–40 mg/kg/day is a prescribing-information range that depends on formulation and indication. Do not convert it directly into an in vitro concentration; follow the FDA label.
• Mechanistic readouts: Pair labile-iron measurements with mitochondrial ROS, NF-κB activity, ferritin and ferritinophagy markers, lysosomal pH or membrane permeability, and cell-death markers. This workflow recommendation distinguishes mechanism from a single viability measurement.
• Storage: Store the supplied solid at −20 °C. The product information does not recommend long-term storage of prepared solutions. Prepare working solutions near the experiment and document solvent, concentration, and freeze-thaw history.

Conclusion & Outlook

Deferasirox is best defined first as an oral iron chelator for transfusion-related iron overload. Its Fe³⁺ binding, reported 2:1 stoichiometry, oral dosing, and iron-disposition profile provide a strong clinical and biochemical foundation. Its mitochondrial ROS and transcriptional effects provide additional experimental endpoints.

The TCF25 study adds a valuable lysosomal nutrient-stress context. It supports testing how ferritin turnover, lysosomal acidification, and iron chelation interact under glucose deprivation. It does not justify assigning TCF25, V-ATPase, ferroptosis, or apoptosis as the primary deferasirox target without direct experiments.

For translational work, the most defensible outlook is comparative. Measure iron availability, oxygen status, lysosomal behavior, redox state, and defined death-pathway markers in the same model. Keep iron-overload treatment, oncology hypothesis testing, and nutrient-starvation biology analytically separate until convergent evidence supports a mechanistic bridge.